How Prostate cancer Works

Prostate cancer begins when DNA within prostate cells accumulates critical mutations, particularly in genes that control cell division and death. The most commonly damaged genes include tumor suppressors like TP53 and PTEN, which normally act as cellular brakes, and oncogenes like MYC, which function as growth accelerators. When PTEN loses function, cells can no longer properly regulate the PI3K/AKT pathway, a crucial signaling system that tells cells when to grow and when to stop.

Many prostate cancer mutations affect androgen receptor genes, which respond to testosterone and other male hormones. These receptors normally control healthy prostate growth, but mutations can make them overly sensitive to hormones or allow them to activate without any hormonal signal at all. Some men inherit mutations in DNA repair genes like BRCA1 and BRCA2—the same genes linked to breast cancer—which dramatically increase their prostate cancer risk because damaged DNA cannot be properly fixed.

Unlike cancers caused by a single catastrophic mutation, prostate cancer typically develops through an accumulation of genetic errors over decades. Environmental factors like diet and inflammation can accelerate this damage, while age itself increases mutation frequency simply because cells have undergone more divisions, each offering another opportunity for copying errors in the genetic code.

Normal prostate cells divide only when the body needs new tissue for growth or repair, then stop when they receive biochemical signals indicating sufficient cells exist. In prostate cancer, mutations disable the checkpoints that enforce these limits, allowing cells to progress through the division cycle without proper authorization. The cell cycle normally has multiple inspection points—particularly the G1/S checkpoint—where damaged or unprepared cells are stopped, but cancer cells bypass these safeguards entirely.

Androgens, particularly testosterone and its more potent derivative dihydrotestosterone (DHT), fuel this uncontrolled multiplication in most prostate cancers. These hormones bind to androgen receptors inside prostate cells, triggering a cascade of signals that activate growth-promoting genes. While normal prostate tissue requires androgens for maintenance and responds proportionally, cancer cells exploit this system, often amplifying androgen receptor genes to become hypersensitive to even tiny hormone amounts.

The unchecked division creates an expanding mass within the prostate gland, initially forming what pathologists call prostatic intraepithelial neoplasia (PIN), a precancerous condition. As mutations accumulate further, these abnormal cells lose additional growth controls, dividing faster and losing the specialized characteristics that made them functional prostate tissue. This exponential growth eventually overwhelms the normal prostate architecture, forming a detectable tumor that may be found during screening tests measuring prostate-specific antigen (PSA) levels in blood.

The prostate gland is enclosed by a fibrous capsule, a protective boundary that contains normal prostate tissue. Prostate cancer cells must break through this capsule and the basement membrane—a thin protein layer that separates tissue compartments—to invade beyond their origin site. Cancer cells achieve this by secreting enzymes called matrix metalloproteinases (MMPs) that digest collagen and other structural proteins, essentially cutting molecular doorways through these barriers.

As cancer cells become more aggressive, they undergo changes that make invasion easier, losing cell-adhesion molecules called E-cadherins that normally keep epithelial cells stuck together in organized sheets. This process, called epithelial-mesenchymal transition (EMT), transforms stationary prostate cells into mobile invaders capable of squeezing through tissue gaps. Cancer cells also manipulate the surrounding environment, recruiting blood vessels through angiogenesis and reprogramming nearby normal cells to support rather than resist the invasion.

Locally invasive prostate cancer commonly infiltrates the seminal vesicles, which lie adjacent to the prostate, and can extend into the bladder neck or rectum. The cancer's Gleason score, determined by examining biopsy tissue under a microscope, reflects how abnormal and invasive the cells appear—higher scores indicate more aggressive patterns of invasion. Perineural invasion, where cancer cells spread along nerve sheaths like wires in a cable, represents a particularly concerning pattern that facilitates cancer's journey beyond the prostate boundaries.

Prostate cancer spreads when invasive cells enter either the lymphatic system or bloodstream, obtaining transportation networks to distant body sites. The pelvic lymph nodes typically serve as the first stop for metastatic prostate cancer cells, acting as filters that inadvertently trap migrating cancer cells. From there, cancer can progress to more distant lymph nodes or enter the venous system through connections between lymphatic vessels and veins.

Prostate cancer exhibits a striking preference for bone metastasis, particularly affecting the spine, pelvis, ribs, and femur. This bone-seeking behavior occurs because prostate cancer cells express receptors that recognize chemical signals released by bone tissue, essentially following a molecular homing beacon. Unlike many cancers that destroy bone (osteolytic metastases), prostate cancer metastases are typically osteoblastic, meaning they stimulate excessive new bone formation that appears dense on imaging scans but is structurally weak and painful.

The metastatic process requires cancer cells to survive numerous challenges: detaching from the primary tumor, surviving in circulation without the structural support of surrounding tissue, adhering to the new site, and establishing a supportive microenvironment. Most circulating tumor cells die during this journey, but the few survivors can remain dormant in distant sites for years before suddenly proliferating. Advanced imaging techniques like bone scans and PSMA PET scans can detect these metastases by identifying areas of abnormal metabolic activity or concentrations of prostate-specific membrane antigen.

Since most prostate cancers depend on androgens for growth, androgen deprivation therapy (ADT) serves as a frontline treatment, using medications or surgical castration to eliminate testosterone. Initially, this hormone starvation causes dramatic tumor shrinkage as cancer cells, deprived of their growth fuel, stop dividing or die. However, within months to years, most advanced cancers develop resistance, transforming into castration-resistant prostate cancer (CRPC) that grows despite negligible testosterone levels.

Resistance develops through several mechanisms, most involving the androgen receptor itself. Cancer cells may amplify the androgen receptor gene, producing so many receptors that they can detect and respond to trace hormone amounts remaining after ADT. Other tumors acquire mutations that make androgen receptors promiscuous, allowing activation by other steroids like estrogen or even receptor-targeted drugs meant to block them. Some cancer cells begin manufacturing their own androgens internally, creating a self-sufficient hormone supply independent of the testes or adrenal glands.

Beyond hormone resistance, prostate cancers develop resistance to chemotherapy drugs like docetaxel through pumps that expel toxic drugs from cells and DNA repair mechanisms that fix chemotherapy-induced damage. A particularly concerning development is neuroendocrine differentiation, where prostate cancer cells transform into a different cell type entirely, abandoning their dependence on androgen receptors and becoming insensitive to hormone-based treatments. Modern treatment approaches attempt to overcome resistance through combination therapies, rotating drugs with different mechanisms, and targeting resistance pathways themselves, though cancer's evolutionary capacity continues to pose challenges.